BRISTOL MYERS SQUIBB CO
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Ticker / security symbols
- BMY, CELG-RI [1]
- Listing exchanges
- NYSE [1]
- SEC industry
- Pharmaceutical Preparations [1]
- Business sectors
- pharmaceutical industry [2]
- Company / filing name
- BRISTOL MYERS SQUIBB CO [1]
- Headquarters location
- New York City [2]
- Business address
- ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543 [1]
- Founded
- 1989 [2]
- Legal form
- Delaware corporation [2]
- Incorporation jurisdiction
- Delaware, United States [1]
- Leadership in background record
- Giovanni Caforio [2]
- Official website
- www.bms.com ↗ [2]
- Employees
- 30,000 · reported year 2019 [2]
- Annual revenue
- USD 46,159,000,000 · reported year 2022 [2]
- Fiscal year end
- December 31 (SEC record) [1]
- ISIN (reported securities)
- US1101221083 [2]
- CIK
- 0000014272 [1]
- SIC code
- 2834 [1]
- Country in background record
- United States [2]
Company positioning and business
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States. [3]
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. [3]
BMS's primary research and development (R&D) sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton), Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey; Redwood City, California; and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts; Braine-l'Alleud, Belgium; Tokyo, Japan; Hyderabad; Bangalore, India and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers). [3]
Background text: Wikipedia contributors, Bristol Myers Squibb. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Management and corporate governance
The Wikidata background record identifies Giovanni Caforio in the chief-executive role. This background entry is not an official confirmation of the current board or executive roster. [2]
Understanding company scale
Employees: 30,000 · reported year 2019. [2]
Annual revenue: USD 46,159,000,000 · reported year 2022. [2]
Financial year, securities and disclosures
The SEC submissions record gives BRISTOL MYERS SQUIBB CO a fiscal year end of 1231 (MMDD). Individual filings below identify their own reporting period; the filing date is the publication event, not the financial year end. [1]
Listed securities: BMY (NYSE), CELG-RI (NYSE). Multiple symbols may represent different share classes or securities of the same registrant. [4]
History and key events
Financial results and regulatory disclosures
Annual, quarterly and current reports from the collected SEC record. Insider Forms 4 and 144 are excluded. This is a selected list, not a live filing feed.
Source-verified relationships
Companies in the same industry
Comparison candidates share the SEC SIC classification 2834. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was BRISTOL MYERS SQUIBB CO founded?
Founded: 1989. The linked source provides the background record. [2]
Where is the headquarters of BRISTOL MYERS SQUIBB CO?
Headquarters location: New York City. The linked source provides the background record. [2]
Which business sectors are recorded for BRISTOL MYERS SQUIBB CO?
Business sectors: pharmaceutical industry. The linked source provides the background record. [2]
BRISTOL MYERS SQUIBB CO relationship map
Select a node to inspect its relationship and source.
2 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- SEC — BRISTOL MYERS SQUIBB CO filing identity and securities ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — Bristol Myers Squibb (CC BY-SA 4.0) ↗
- SEC securities directory ↗
- Company chronology / filing ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.